Allergan's Restasis Defense Falters As PTAB Dismisses Tribal Immunity Ploy
The damage inflicted by Mylan and other manufacturers looking to sell Restasis generics already has been felt by Allergan, but the PTAB dealt the dry eye drug's patent defense another blow by rejecting the Mohawk Tribe's plea to have an inter partes review thrown out.
You may also be interested in...
Brent Saunder’s Vesper Healthcare Acquisition Corp. wants to raise up to $460m in a forthcoming IPO to buy companies in health care and medical market niches including wellness.
Public Company Edition: The former Allergan CEO is taking a special purpose acquisition corporation public to generate $460m for deals in familiar biopharma niches. Also, IPOs are expected to keep up a robust pace in the fall and Albireo raises $160m on the success of its drug for pediatric liver diseases.
Allergan was expected to announce soon that it would follow its shareholders' advice and split the company in two, but it's being acquired by AbbVie for $63bn instead, finally giving investors a big boost in their Allergan holdings after years of decline.